These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 29856291)
1. Clinician-reported changes in octreotide prescribing for malignant bowel obstruction as a result of an adequately powered phase III study: A transnational, online survey. Campbell R; McCaffrey N; Brown L; Agar MR; Clark K; Currow DC Palliat Med; 2018 Sep; 32(8):1363-1368. PubMed ID: 29856291 [TBL] [Abstract][Full Text] [Related]
2. Health-related quality of life in patients with inoperable malignant bowel obstruction: secondary outcome from a double-blind, parallel, placebo-controlled randomised trial of octreotide. McCaffrey N; Asser T; Fazekas B; Muircroft W; Agar M; Clark K; Eckermann S; Lee J; Joshi R; Allcroft P; Sheehan C; Currow DC BMC Cancer; 2020 Oct; 20(1):1050. PubMed ID: 33129304 [TBL] [Abstract][Full Text] [Related]
3. Octreotide prescribing patterns in the palliation of symptomatic inoperable malignant bowel obstruction patients at a single US academic hospital. Hwang M; Pirrello R; Pu M; Messer K; Roeland E Support Care Cancer; 2013 Oct; 21(10):2817-24. PubMed ID: 23732621 [TBL] [Abstract][Full Text] [Related]
5. Practice Patterns of Medications for Patients With Malignant Bowel Obstruction Using a Nationwide Claims Database and the Association Between Treatment Outcomes and Concomitant Use of H Minoura T; Takeuchi M; Morita T; Kawakami K J Pain Symptom Manage; 2018 Feb; 55(2):413-419.e2. PubMed ID: 29122616 [TBL] [Abstract][Full Text] [Related]
6. Implementing practice change in chronic cancer pain management: clinician response to a phase III study of ketamine. Hardy JR; Spruyt O; Quinn SJ; Devilee LR; Currow DC Intern Med J; 2014 Jun; 44(6):586-91. PubMed ID: 24720500 [TBL] [Abstract][Full Text] [Related]
7. Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction. Currow DC; Quinn S; Agar M; Fazekas B; Hardy J; McCaffrey N; Eckermann S; Abernethy AP; Clark K J Pain Symptom Manage; 2015 May; 49(5):814-21. PubMed ID: 25462210 [TBL] [Abstract][Full Text] [Related]
9. The palliative effects of octreotide in malignant disease. Dean A; Bridge D; Lickiss JN Ann Acad Med Singap; 1994 Mar; 23(2):212-5. PubMed ID: 7521613 [TBL] [Abstract][Full Text] [Related]
10. Octreotide in the management of bowel obstruction in terminal ovarian cancer. Mangili G; Franchi M; Mariani A; Zanaboni F; Rabaiotti E; Frigerio L; Bolis PF; Ferrari A Gynecol Oncol; 1996 Jun; 61(3):345-8. PubMed ID: 8641613 [TBL] [Abstract][Full Text] [Related]
11. Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction. Hisanaga T; Shinjo T; Morita T; Nakajima N; Ikenaga M; Tanimizu M; Kizawa Y; Maeno T; Shima Y; Hyodo I Jpn J Clin Oncol; 2010 Aug; 40(8):739-45. PubMed ID: 20410056 [TBL] [Abstract][Full Text] [Related]
12. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Mercadante S; Ripamonti C; Casuccio A; Zecca E; Groff L Support Care Cancer; 2000 May; 8(3):188-91. PubMed ID: 10789958 [TBL] [Abstract][Full Text] [Related]
13. Pathophysiology and palliation of inoperable bowel obstruction in patients with ovarian cancer. Jatoi A; Podratz KC; Gill P; Hartmann LC J Support Oncol; 2004; 2(4):323-34; discussion 334-7. PubMed ID: 15357517 [TBL] [Abstract][Full Text] [Related]
14. Radiological imaging change in a malignant bowel obstruction patient treated with octreotide. Shinjo T; Kagami R Support Care Cancer; 2009 Jun; 17(6):753-5. PubMed ID: 19277723 [TBL] [Abstract][Full Text] [Related]
15. Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double- blind, controlled clinical trial. Mystakidou K; Tsilika E; Kalaidopoulou O; Chondros K; Georgaki S; Papadimitriou L Anticancer Res; 2002; 22(2B):1187-92. PubMed ID: 12168923 [TBL] [Abstract][Full Text] [Related]
16. Clinical impact of palliative treatment using octreotide for inoperable malignant bowel obstruction caused by advanced urological cancer. Kubota H; Taguchi K; Kobayashi D; Naruyama H; Hirose M; Fukuta K; Kubota Y; Yasui T; Yamada Y; Kohri K Asian Pac J Cancer Prev; 2013; 14(12):7107-10. PubMed ID: 24460259 [TBL] [Abstract][Full Text] [Related]
17. How to use octreotide for malignant bowel obstruction. Ripamonti C; Mercadante S J Support Oncol; 2004; 2(4):357-64. PubMed ID: 15357519 [No Abstract] [Full Text] [Related]
18. Evaluation of Guideline Adherence in Colorectal Cancer Treatment in The Netherlands: A Survey Among Medical Oncologists by the Dutch Colorectal Cancer Group. Keikes L; van Oijen MGH; Lemmens VEPP; Koopman M; Punt CJA Clin Colorectal Cancer; 2018 Mar; 17(1):58-64. PubMed ID: 29157662 [TBL] [Abstract][Full Text] [Related]
20. A prospective study on the efficacy of octreotide in the management of malignant bowel obstruction in gynecologic cancer. Watari H; Hosaka M; Wakui Y; Nomura E; Hareyama H; Tanuma F; Hattori R; Azuma M; Kato H; Takeda N; Ariga S; Sakuragi N Int J Gynecol Cancer; 2012 May; 22(4):692-6. PubMed ID: 22343971 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]